Abstract
In vitro–transcribed mRNA (IVT mRNA) is emerging as a new class of drug that has the potential to play a role in gene therapy that once was envisioned for DNA.1 Although first described as a therapeutic in 1992,2 IVT mRNA’s immunogenicity prevented its development for protein replacement therapies. However, this problem was recently solved by the introduction of modified nucleosides into the IVT mRNA.3 In this issue of Molecular Therapy, Thess and colleagues report an alternative method for generating nonimmunogenic IVT mRNA that avoids the use of modified nucleosides.4 They demonstrate that sequence engineering of the mRNA and purifying it with high performance liquid chromatography are sufficient to avoid immune activation and to achieve high levels of translation of the encoded protein both in vitro and in vivo.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
